ELV - Elevance Health, Inc. Stock Price, Fair Value and News

533.73USD+0.81 (+0.15%)Market Closed

Market Summary

USD533.73+0.81

Market Closed

0.15%

ELV Stock Price

View Fullscreen

ELV RSI Chart

ELV Valuation

Market Cap

124.1B

Price/Earnings (Trailing)

19.89

Price/Sales (Trailing)

0.72

EV/EBITDA

13.07

Price/Free Cashflow

54.03

ELV Price/Sales (Trailing)

ELV Profitability

EBT Margin

4.68%

Return on Equity

15.32%

Return on Assets

5.57%

Free Cashflow Yield

1.85%

ELV Fundamentals

ELV Revenue

Revenue (TTM)

171.7B

Rev. Growth (Yr)

0.96%

Rev. Growth (Qtr)

-0.16%

ELV Earnings

Earnings (TTM)

6.2B

Earnings Growth (Yr)

12.08%

Earnings Growth (Qtr)

165.17%

Breaking Down ELV Revenue

Last 7 days

4.9%

Last 30 days

4.6%

Last 90 days

11.1%

Trailing 12 Months

15.8%

How does ELV drawdown profile look like?

ELV Financial Health

Current Ratio

1.37

Debt/Equity

0.54

Debt/Cashflow

0.16

ELV Investor Care

Dividend Yield

1.14%

Dividend/Share (TTM)

6.07

Buy Backs (1Y)

1.98%

Diluted EPS (TTM)

26.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	171.7B	0	0	0
2023	160.7B	165.7B	168.6B	171.3B
2022	144.3B	149.1B	153.2B	156.6B
2021	124.6B	129.2B	133.9B	138.6B
2020	109.2B	113.0B	117.5B	121.9B
2019	94.2B	96.8B	100.2B	104.2B
2018	90.1B	90.6B	91.4B	92.1B
2017	87.1B	88.1B	89.1B	90.0B
2016	80.4B	81.8B	83.3B	84.9B
2015	75.1B	76.6B	78.0B	79.2B
2014	71.3B	72.1B	72.8B	73.9B
2013	63.7B	66.0B	68.6B	71.0B
2012	61.2B	61.5B	61.4B	61.5B
2011	58.5B	59.2B	60.0B	60.7B
2010	65.0B	64.0B	63.1B	58.7B
2009	60.8B	60.6B	61.1B	65.0B
2008	0	61.2B	61.2B	61.3B
2007	0	0	0	61.2B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Elevance Health, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 08, 2024	kendrick charles morgan jr	sold	-1,217,120	500	-2,432	evp & president, commercial
Mar 06, 2024	penczek ronald w	sold	-462,195	504	-916	cao & controller
Mar 04, 2024	haytaian peter d	sold	-10,551,300	500	-21,095	evp & pres carelon & carelonrx
Mar 04, 2024	haytaian peter d	acquired	2,504,550	166	15,000	evp & pres carelon & carelonrx
Mar 01, 2024	boudreaux gail	sold (taxes)	-9,610,860	499	-19,256	president and ceo
Mar 01, 2024	kendrick charles morgan jr	acquired	-	-	4,508	evp & president, commercial
Mar 01, 2024	norwood felicia f	sold (taxes)	-2,446,640	499	-4,902	evp & president,gov health ben
Mar 01, 2024	kaye mark	acquired	-	-	2,755	evp & cfo
Mar 01, 2024	norwood felicia f	acquired	-	-	11,557	evp & president,gov health ben
Mar 01, 2024	penczek ronald w	acquired	-	-	1,272	cao & controller

Which funds bought or sold ELV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-14.81	-1,716,000	25,435,000	0.22%
Apr 23, 2024	BSW Wealth Partners	sold off	-100	-288,925	-	-%
Apr 23, 2024	WEDGE CAPITAL MANAGEMENT L L P/NC	added	22.21	10,313,100	40,307,200	0.65%
Apr 23, 2024	Main Street Financial Solutions, LLC	new	-	219,456	219,456	0.02%
Apr 23, 2024	Canal Capital Management, LLC	reduced	-20.88	-47,325	318,384	0.05%
Apr 23, 2024	DUNCKER STREETT & CO INC	reduced	-40.04	-1,203,650	2,329,280	0.46%
Apr 23, 2024	WESBANCO BANK INC	reduced	-1.91	54,262	744,627	0.03%
Apr 23, 2024	Tennessee Valley Asset Management Partners	sold off	-100	-4,856	-	-%
Apr 23, 2024	Busey Bank	added	1.49	91,703	882,036	0.03%
Apr 23, 2024	NEW MEXICO EDUCATIONAL RETIREMENT BOARD	reduced	-4.05	321,000	6,143,000	0.22%

Are Funds Buying or Selling ELV?

Are funds buying ELV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ELV

No. of Funds

Unveiling Elevance Health, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	5.1%	11,929,862	SC 13G
Feb 13, 2024	vanguard group inc	9.03%	21,227,022	SC 13G/A
Feb 12, 2024	blackrock inc.	9.0%	21,044,185	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	5.3%	12,717,041	SC 13G
Feb 09, 2023	vanguard group inc	8.99%	21,473,444	SC 13G/A
Jan 27, 2023	blackrock inc.	9.0%	21,566,516	SC 13G/A
Jan 25, 2023	blackrock inc.	9.0%	21,566,516	SC 13G/A

Recent SEC filings of Elevance Health, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	144	Notice of Insider Sale Intent
Apr 22, 2024	DEFA14A	DEFA14A
Apr 18, 2024	10-Q	Quarterly Report
Apr 18, 2024	8-K	Current Report
Mar 29, 2024	DEF 14A	DEF 14A
Mar 29, 2024	DEFA14A	DEFA14A
Mar 12, 2024	4	Insider Trading
Mar 08, 2024	144	Notice of Insider Sale Intent
Mar 08, 2024	4	Insider Trading
Mar 06, 2024	144	Notice of Insider Sale Intent

Elevance Health, Inc. News

Latest updates

Elevance Health, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-0.2%	42,577	42,647	42,849	43,672	42,172	39,929	39,939	38,632	38,095	36,581	35,822	33,851	32,385	31,824	31,158	29,264	29,621	27,407	26,674	25,466	24,666
S&GA Expenses	-2.3%	4,886	4,999	5,470	4,818	4,800	4,567	4,516	4,272	4,345	4,226	3,946	3,821	3,925	4,318	5,305	4,046	3,781	3,502	3,418	3,278	3,166
EBITDA Margin	1.7%	0.06*	0.06*	0.06*	0.07*	0.07*	0.06*	0.07*	0.07*	0.07*	0.07*	0.07*	0.06*	0.07*	0.07*	0.07*	0.09*	0.07*	-	-	-	-
Interest Expenses	2.3%	265	259	259	261	251	229	213	208	201	200	201	205	192	191	198	201	194	190	185	184	187
Income Taxes	305.9%	690	170	354	585	615	168	529	488	527	291	494	552	509	60.00	167	873	566	164	306	314	394
Earnings Before Taxes	193.6%	2,939	1,001	1,654	2,441	2,619	1,045	2,127	2,122	2,306	1,470	1,996	2,353	2,176	611	389	3,149	2,089	1,098	1,489	1,453	1,945
EBT Margin	3.9%	0.05*	0.05*	0.05*	0.05*	0.05*	0.05*	0.05*	0.05*	0.06*	0.06*	0.05*	0.04*	0.05*	0.05*	0.06*	0.07*	0.06*	-	-	-	-
Net Income	165.2%	2,246	847	1,289	1,856	2,004	872	1,603	1,634	1,779	1,186	1,509	1,801	1,667	551	222	2,276	1,523	934	1,183	1,139	1,551
Net Income Margin	3.8%	0.04*	0.03*	0.04*	0.04*	0.04*	0.04*	0.04*	0.04*	0.04*	0.04*	0.04*	0.03*	0.04*	0.04*	0.04*	0.05*	0.04*	-	-	-	-
Free Cashflow	151.5%	1,699	-3,297	2,294	1,600	6,168	-1,816	4,619	2,157	2,287	1,332	2,246	1,398	2,301	3,535	-1,456	5,277	2,311	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	2.7%	111,894	108,928	110,478	109,168	109,040	102,755	103,026	100,877	100,486	97,456	98,060	96,097	95,683	86,615	86,574	87,976	82,399	77,453	77,809	75,851	74,523
Current Assets	1.5%	60,948	60,029	61,185	59,743	59,823	55,617	55,603	53,655	53,897	51,122	51,904	50,238	54,495	45,751	45,450	46,764	41,256	39,033	39,504	37,805	36,611
Cash Equivalents	-4.6%	6,226	6,526	10,919	9,991	10,142	7,387	8,872	6,456	6,161	4,880	5,490	5,258	9,326	5,741	3,984	6,028	5,345	4,937	4,190	4,078	4,482
Net PPE	2.1%	4,451	4,359	4,248	4,547	4,418	4,316	4,197	4,090	3,986	3,919	3,835	3,733	3,533	3,483	3,363	3,427	3,350	3,133	2,921	2,837	2,799
Goodwill	2.5%	25,947	25,317	25,291	25,274	25,273	24,383	24,381	24,367	24,251	24,228	24,184	24,399	21,708	21,691	21,687	21,641	21,661	20,500	20,500	20,500	20,500
Liabilities	2.4%	71,184	69,523	71,939	70,856	71,580	66,425	66,983	65,010	64,455	61,293	62,252	61,051	61,765	53,416	52,653	53,521	50,706	45,725	46,477	45,058	44,525
Current Liabilities	6.1%	44,334	41,791	43,337	41,571	41,889	39,696	41,287	39,308	39,733	34,885	35,162	33,794	34,749	29,453	28,561	28,522	27,039	23,532	23,234	23,090	22,682
Short Term Borrowings	600.0%	1,575	225	-	265	265	265	265	175	275	275	175	175	-	-	150	-	1,075	700	710	1,010	1,095
Long Term Debt	-5.5%	21,976	23,246	24,045	24,859	25,201	22,349	21,258	21,165	19,883	21,157	21,761	22,217	22,534	19,335	19,094	19,873	19,005	17,787	18,820	17,436	17,396
LT Debt, Current	75.9%	2,900	1,649	799	-	-	1,500	2,249	2,248	3,097	1,599	849	849	700	700	1,599	1,603	1,603	1,598	700	850	851
LT Debt, Non Current	-100.0%	-	23,246	24,045	24,859	25,201	22,349	21,258	21,165	19,883	21,157	21,761	22,217	22,534	19,335	19,094	19,873	19,005	17,787	18,820	17,436	17,396
Shareholder's Equity	3.6%	40,710	39,306	38,423	38,312	37,460	36,243	36,055	35,887	36,059	36,163	35,808	35,046	33,918	33,187	33,921	34,455	31,693	31,693	31,332	30,793	29,998
Retained Earnings	4.2%	33,088	31,749	32,103	31,608	30,707	29,647	29,604	28,825	28,058	27,142	26,700	25,874	24,793	23,802	24,678	25,346	23,360	22,573	22,104	21,679	21,136
Additional Paid-In Capital	0.2%	8,883	8,868	8,830	8,761	8,697	9,084	9,169	9,134	9,151	9,148	9,138	9,109	9,253	9,244	9,352	9,360	9,338	9,448	9,524	9,494	9,482
Shares Outstanding	-0.3%	232	233	235	236	237	238	239	240	241	242	243	244	245	245	249	252	252	-	-	-	-
Minority Interest	3.0%	102	99.00	116	107	104	87.00	52.00	55.00	56.00	68.00	71.00	78.00	65.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	104,634	-	-	-	115,692	-	-	-	93,008	-	-	-	66,231	-	-	-	72,160	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	166.6%	1,978	-2,971	2,613	1,950	6,469	-1,518	4,924	2,452	2,541	1,672	2,504	1,683	2,505	3,813	-1,150	5,510	2,515	1,327	1,667	1,437	1,630
Share Based Compensation	-13.9%	62.00	72.00	78.00	78.00	61.00	73.00	69.00	72.00	50.00	59.00	63.00	69.00	64.00	69.00	80.00	67.00	67.00	68.00	86.00	70.00	70.00
Cashflow From Investing	-124.5%	-2,310	-1,029	-687	-672	-3,184	289	-1,247	-2,024	-1,578	-966	-1,440	-4,925	-2,307	305	89.00	-4,934	-2,784	723	-1,698	-1,165	-652
Cashflow From Financing	108.1%	32.00	-394	-994	-1,430	-531	-258	-1,255	-127	322	-1,315	-830	-820	3,388	-2,367	-984	105	679	-1,304	144	-677	-429
Dividend Payments	-100.0%	-	346	348	350	351	305	306	309	309	273	276	278	277	234	238	242	240	202	204	206	206
Buy Backs	-40.2%	566	946	485	652	575	568	579	624	545	522	451	480	447	1,358	758	55.00	529	305	644	458	294

ELV Income Statement

2024-03-31

Consolidated Statements of Income - USD ($) $ in Millions	3 Months Ended
Consolidated Statements of Income - USD ($) $ in Millions	Mar. 31, 2024	Mar. 31, 2023
Revenues
Premiums	$ 35,696	$ 35,868
Total operating revenue	42,273	41,898
Net investment income	465	387
Net losses on financial instruments	(161)	(113)
Total revenues	42,577	42,172
Expenses
Benefit expense	30,546	30,786
Cost of products sold	3,825	3,481
Operating expense	4,886	4,800
Interest expense	265	251
Amortization of other intangible assets	116	235
Total expenses	39,638	39,553
Income before income tax expense	2,939	2,619
Income tax expense	690	615
Net income	2,249	2,004
Net income attributable to noncontrolling interests	(3)	(15)
Shareholders’ net income	$ 2,246	$ 1,989
Shareholders’ net income per share
Basic (in dollars per share)	$ 9.65	$ 8.37
Diluted (in dollars per share)	9.59	8.30
Dividends per share (in dollars per share)	$ 1.63	$ 1.48
Product revenue
Revenues
Product and service revenue	$ 4,499	$ 4,022
Service fees
Revenues
Product and service revenue	$ 2,078	$ 2,008

ELV Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,226	$ 6,526
Fixed maturity securities (amortized cost of $30,427 and $30,446; allowance for credit losses of $4 and $4)	29,530	29,614
Equity securities	511	229
Premium receivables	8,931	7,902
Self-funded receivables	4,242	4,558
Other receivables	5,120	5,405
Other current assets	6,388	5,795
Total current assets	60,948	60,029
Long-term investments:
Fixed maturity securities (amortized cost of $902 and $890; allowance for credit losses of $0 and $0)	880	876
Other invested assets	6,713	6,107
Property and equipment, net	4,451	4,359
Goodwill	25,947	25,317
Other intangible assets	10,710	10,273
Other noncurrent assets	2,245	1,967
Total assets	111,894	108,928
Current liabilities:
Medical claims payable	16,459	16,111
Other policyholder liabilities	5,298	5,600
Unearned income	1,474	1,402
Accounts payable and accrued expenses	5,658	6,910
Short-term borrowings	1,575	225
Current portion of long-term debt	2,900	1,649
Other current liabilities	10,970	9,894
Total current liabilities	44,334	41,791
Long-term debt, less current portion	21,976	23,246
Reserves for future policy benefits	765	778
Deferred tax liabilities, net	2,201	1,970
Other noncurrent liabilities	1,908	1,738
Total liabilities	71,184	69,523
Commitments and contingencies – Note 11
Shareholders’ equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none	0	0
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 232,544,717 and 233,071,088	2	2
Additional paid-in capital	8,883	8,868
Retained earnings	33,088	31,749
Accumulated other comprehensive loss	(1,365)	(1,313)
Total shareholders’ equity	40,608	39,306
Noncontrolling interests	102	99
Total equity	40,710	39,405
Total liabilities and equity	$ 111,894	$ 108,928

About Elevance Health, Inc.

Elevance Health, Inc. operates as a health benefits company. The company operates through four segments: Commercial & Specialty Business, Government Business, CarelonRx, and Other. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was founded in 1944 and is based in Indianapolis, Indiana.

CEO	Ms. Gail Koziara Boudreaux
WEBSITE	elevancehealth.com
INDUSTRY	Healthcare Plans
EMPLOYEES	65535

Elevance Health, Inc. Frequently Asked Questions

What is the ticker symbol for Elevance Health, Inc.? What does ELV stand for in stocks?

ELV is the stock ticker symbol of Elevance Health, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Elevance Health, Inc. (ELV)?

As of Wed Apr 24 2024, market cap of Elevance Health, Inc. is 124.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ELV stock?

You can check ELV's fair value in chart for subscribers.

What is the fair value of ELV stock?

You can check ELV's fair value in chart for subscribers. The fair value of Elevance Health, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Elevance Health, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ELV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Elevance Health, Inc. a good stock to buy?

The fair value guage provides a quick view whether ELV is over valued or under valued. Whether Elevance Health, Inc. is cheap or expensive depends on the assumptions which impact Elevance Health, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELV.

What is Elevance Health, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, ELV's PE ratio (Price to Earnings) is 19.89 and Price to Sales (PS) ratio is 0.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Elevance Health, Inc.'s stock?

In the past 10 years, Elevance Health, Inc. has provided 0.201 (multiply by 100 for percentage) rate of return.